Monoclonal Antibody News and Research RSS Feed - Monoclonal Antibody News and Research

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Further Reading
Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis gets three FDA approvals for expanded use of biologic drug to treat rare autoinflammatory diseases

Novartis announced today that the US Food and Drug Administration has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes. [More]
Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

Novel Trojan Horse antibody strategy may target Ebola's Achilles' heel

In research published online today in Science, a team of scientists describe a new therapeutic strategy to target a hidden Achilles' heel shared by all known types of Ebola virus. [More]
Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding. [More]
Added benefit not proven for new combination therapy in multiple myeloma

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment. [More]
Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab. [More]
LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

As an arm of the innate immune system, white blood cells called neutrophils form the first line of defense against invading pathogens. [More]
Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. [More]
Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours. [More]
New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

A new measurement standard developed by the National Institute of Standards of Technology has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer. [More]
New drug provides considerable added benefit in treating adults with advanced renal cell cancer

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy. [More]
CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

CTCA at Western begins clinical trial for novel antibody to treat patients with advanced tumors

Cancer Treatment Centers of America at Western Regional Medical Center has dosed its first three patients as part of the launch of a Phase I clinical trial using a novel antibody to treat patients with advanced solid tumors. [More]
Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists have engineered a sort of biological barbell that can get inside cancer cells and do damage to two proteins that work independently and together to enable cancer's survival and spread. [More]
Advances in head and neck cancer treatments: an interview with Prof. Argiris

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Patients with head and neck cancer usually present with locally advanced disease and often require more than one type of treatment, which may include surgery, radiotherapy, and chemotherapy. [More]
Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Researchers at UC Davis and Ionis Pharmaceuticals have developed a hybrid treatment that harnesses a monoclonal antibody to deliver antisense DNA to acute lymphoblastic leukemia (ALL) cells and that may lead to less toxic treatments for the disease. [More]
Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

To support a coordinated, innovative approach to the development of an AIDS vaccine, Texas Biomedical Research Institute scientists, together with a multi-institutional coalition of experts from the United States and Europe, have received a grant for $23 million from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Inserm Unit U919, directed by Prof. Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis. [More]
Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

A team of researchers from the Institute for Research in Biomedicine and the Swiss biotech company Humabs BioMed SA has identified novel therapeutic monoclonal antibody candidates isolated from Zika-infected patients and new strategies for Zika virus diagnostics. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
Advertisement
Advertisement